Atypical Antipsychotics and Weight Gain in Chinese Patients: A Comparison of Olanzapine and Risperidone
J Clin Psychiatry 2004;65:864-866
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To compare the effect of olanzapine with that of risperidone on weight change among Chinese patients in Hong Kong.
Method: The body weight of subjects maintained on olanzapine or risperidone treatment was recorded at the outpatient clinic of a teaching hospital. Pretreatment weight of the subjects was retrieved from case records. Subjects on olanzapine treatment were matched in sex, age, and diagnosis with those on risperidone treatment, and demographic and clinical data were analyzed. The study was conducted in May and June 2002.
Results: Twenty-eight olanzapine-risperidone matched pairs were studied. All were diagnosed with DSM-IV schizophrenia. In patients treated with olanzapine and risperidone, respectively, mean ± SD duration of treatment with atypical neuroleptics was 103.5 ± 47.4 weeks and 93.2 ± 50.6 weeks (range, 21-255 weeks), and mean doses were 12.4 ± 6.7 mg/day and 4.5 ± 2.8 mg/day. The mean ± SD weight gain of subjects on treatment with olanzapine and risperidone, respectively, was 8.34 ± 5.97 kg (18.53 ± 13.27 lb) and 2.74 ± 8.09 kg (6.09 ± 17.98 lb) with a statistically significant difference at p < .005. Lower baseline body weight and body mass index were associated with greater weight gain in both olanzapine- and risperidone-treated subjects. Gender, age, mean daily dose, and duration of treatment had no effect on weight change.
Conclusion: Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong. The effect of adjunctive anticonvulsant treatment on weight gain requires further study.